DrugPatentWatch Database Preview
CEFADROXIL/CEFADROXIL HEMIHYDRATE - Generic Drug Details
What are the generic drug sources for cefadroxil/cefadroxil hemihydrate and what is the scope of patent protection?
Cefadroxil/cefadroxil hemihydrate
is the generic ingredient in three branded drugs marketed by Aurobindo Pharma, Cspc Ouyi, Hikma, Ivax Sub Teva Pharms, Lupin, Orchid Hlthcare, Purepac Pharm, Ranbaxy Labs Ltd, Sandoz, Teva, Teva Pharms, Warner Chilcott, Bristol, Ani Pharms Inc, Apothecon, Aurobindo, Hikma Pharms, Sun Pharm Inds Ltd, and Ranbaxy, and is included in thirty NDAs. Additional information is available in the individual branded drug profile pages.Twenty suppliers are listed for this compound.
Summary for CEFADROXIL/CEFADROXIL HEMIHYDRATE
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 19 |
NDAs: | 30 |
Suppliers / Packagers: | 20 |
Bulk Api Vendors: | 61 |
Patent Applications: | 6,339 |
DailyMed Link: | CEFADROXIL/CEFADROXIL HEMIHYDRATE at DailyMed |
Pharmacology for CEFADROXIL/CEFADROXIL HEMIHYDRATE
Drug Class | Cephalosporin Antibacterial |
Synonyms for CEFADROXIL/CEFADROXIL HEMIHYDRATE
(6R,7R)-7-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
(6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid |
(6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
(6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
(7R)-7-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
4-Hydroxycephalexin |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R,7R)- |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6-alpha,7-beta(R*)))- |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- |
50370-12-2 |
592C878 |
66592-87-8 |
7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetylamino](7R,7aR)-3-methyl-6-oxo-2H,7H-a zetidino[2,1-b]1,3-thiazine-4-carboxylic acid |
7-[[2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
7-{[amino(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-3,4-didehydrocepham-4-carboxylic acid |
AB00513838 |
AC1L1E2B |
AC1L2J3O |
AC1Q6LPA |
AKOS005622555 |
API0006601 |
AS-11655 |
AS-13773 |
Baxan |
BBL033696 |
BDBM50350467 |
Bidocef |
BL-S578 |
BOEGTKLJZSQCCD-UEKVPHQBSA-N |
BPBio1_000494 |
BSPBio_000448 |
C06878 |
C16H17N3O5S |
CAS-50370-12-2 |
CCG-220434 |
CDX |
Cefa-Drops |
Cefadrops |
cefadroxil |
Cefadroxil (anhydrous) |
Cefadroxil (JP17) |
Cefadroxil [INN] |
Cefadroxil anhydrous |
Cefadroxil monohydrate, Antibiotic for Culture Media Use Only |
Cefadroxil, 95-105% |
Cefadroxil, analytical standard |
Cefadroxil, Anhydrous |
Cefadroxilo |
Cefadroxilo [INN-Spanish] |
Cefadroxilum |
Cefadroxilum [INN-Latin] |
Cefamox |
Cefradroxil |
Cephadroxil |
Cephadroxyl |
Cephos |
CHEBI:3479 |
CHEMBL1555813 |
CHEMBL1644 |
CS-4696 |
CTK8F8512 |
D-Cefadroxil |
D00257 |
DB01140 |
DivK1c_000409 |
DSSTox_CID_2749 |
DSSTox_GSID_22749 |
DSSTox_RID_76714 |
DTXSID8022749 |
Duracef |
Duricef |
EINECS 256-555-6 |
Epitope ID:117131 |
FT-0603067 |
GTPL4831 |
HMS1569G10 |
HMS2096G10 |
HMS3713G10 |
HMS501E11 |
HY-B1190 |
I04-8441 |
IDI1_000409 |
J10293 |
KBio1_000409 |
KBio2_000544 |
KBio2_003112 |
KBio2_005680 |
KBioGR_000732 |
KBioSS_000544 |
Kefroxil |
LS-149956 |
MCULE-6475996520 |
MCULE-6662086355 |
MJF-11567-3 |
MLS002207219 |
MolPort-002-507-346 |
MolPort-006-167-717 |
NCGC00016858-01 |
NCGC00094609-01 |
NCGC00094609-02 |
NCGC00179556-01 |
NCGC00179556-03 |
NINDS_000409 |
NSC-756664 |
NSC756664 |
Oracefal |
p-Hydroxycephalexine |
Pharmakon1600-01500163 |
Prestwick0_000434 |
Prestwick1_000434 |
Prestwick2_000434 |
Prestwick3_000434 |
Q525PA8JJB |
S 578 |
S-578 |
SBI-0051305.P003 |
SC-74593 |
SCHEMBL13698957 |
SCHEMBL151320 |
Sedral |
SMR001306770 |
SPBio_000014 |
SPBio_002387 |
Spectrum_000104 |
Spectrum2_000087 |
Spectrum4_000266 |
Spectrum5_000663 |
ST51014960 |
STK801939 |
Sumacef |
Sumacef (TN) |
Tox21_110651 |
Tox21_110651_1 |
Ultracef |
UNII-Q525PA8JJB |
ZINC3830391 |
US Patents and Regulatory Information for CEFADROXIL/CEFADROXIL HEMIHYDRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Warner Chilcott | DURICEF | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 050527-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Ranbaxy | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | TABLET;ORAL | 065018-001 | Apr 23, 1999 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Teva | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | CAPSULE;ORAL | 062695-001 | Feb 10, 1989 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Aurobindo | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 065349-001 | Apr 25, 2013 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Teva Pharms | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | CAPSULE;ORAL | 065282-001 | Jan 20, 2006 | AB | RX | No | Yes | Start Trial | Start Trial | Start Trial | |||
Hikma | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | TABLET;ORAL | 065260-001 | Mar 30, 2006 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.